Management of chronic spontaneous urticaria (CSU) remains challenging due to frequent patient refractoriness to high-dose H1-antihistamines, necessitating omalizumab therapy. At diagnosis, reliable and accessible biomarkers are critical to predict which patients will require treatment escalation. This study aimed to evaluate baseline hematological parameters and derive inflammatory indices for their capacity to predict maximum H1-antihistamine dose and subsequent need for omalizumab in a homogenous CSU cohort without major comorbidities. This single-center, retrospective cohort study included 185 adult CSU patients. Baseline inflammatory markers were analyzed relative to the primary outcome of omalizumab requirement and secondary outcome of intensity of antihistamine dose. Multivariate logistic regression and receiver operating characteristic analyses identified independent predictors and optimized cut-off values. Higher baseline levels of inflammatory markers, such as white blood cell count, neutrophils, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, and aggregate index of systemic inflammation (AISI), were significantly associated with the need for fourfold antihistamine dosing. Adjusted multivariate analysis identified AISI ≥ 346.8 (adjusted odds ratio [aOR] = 7.45) as an independent predictor of omalizumab requirement, while erythrocyte sedimentation rate (ESR) > 7.5 (aOR = 0.24) was identified as an independent protective factor against omalizumab requirement. As a standalone biomarker, AISI demonstrated an area under the curve (AUC) of 0.733 and a negative predictive value (NPV) of 96.4% at this threshold. In this cohort, baseline AISI was independently associated with omalizumab requirement and appears to be a promising marker that warrants external validation, whereas elevated ESR appears protective. Given the retrospective single-center design, these findings should be interpreted cautiously. A high NPV of the AISI cut-off suggests potential clinical utility for ruling out patients unlikely to require treatment escalation.
In this article, we presented our case who developed CC splenium infarction who had COVID-19 pneumonia at the same time. A 45-year-old male patient with a positive COVID-19 PCR test was admitted to the emergency department with complaints of confusion and loss of direction. He didn’t have a chronic disease, a history of smoking and alcohol abuse. Confusion was found on mental examination. The Splenium of the CC was hyperintense on diffusion-weighted magnetic resonance imaging (MRI) and hypointense on Apparent diffusion coefficient (ADC) sequence. There are a few case reports in the literature about young patients who do not have known or unexplained cardiovascular risk factors and who have had COVID-19-related pneumonia. We thought that COVID-19 pneumonia might be a triggering factor since infarction of the splenium region of the corpus callosum is rare, the patient is in the young age patient group, and there is no other comorbidity.
Background/Objectives: Asthma and inhaled corticosteroids (ICS) may adversely affect voice; however, voice outcomes in patients receiving biologic therapy have not previously been evaluated. This study aimed to evaluate voice outcomes in women with asthma receiving IL-5 pathway-targeted biologic therapy. Methods: This cross-sectional controlled study included 93 women: 27 patients with asthma receiving mepolizumab or benralizumab (Biologic group), 31 patients with asthma not receiving biologic therapy (Non-biologic group), and 35 healthy controls. Acoustic parameters (F0, jitter, shimmer, and harmonics-to-noise ratio [HNR]) and patient-reported measures (Voice Handicap Index-10 [VHI-10], Reflux Symptom Index [RSI], and Leicester Cough Questionnaire [LCQ]) were compared. Multivariable regression analysis adjusted for age and ICS dose was performed for asthmatic patients. Results: Compared to controls, the Non-biologic group showed higher shimmer and lower HNR (both p < 0.001). In the Biologic group, no significant differences in these parameters were observed compared with controls, despite higher ICS doses. Direct comparisons between the Biologic and Non-biologic groups also revealed no significant differences in shimmer or HNR. After adjustment for age and ICS dose, biologic therapy was associated with lower log-transformed shimmer (B = −0.624, q = 0.009) and higher HNR (B = 3.995, q = 0.020), whereas no significant association was found with jitter. Lower LCQ scores and higher RSI scores were observed in both asthma groups than in the control group, whereas VHI-10 scores did not significantly differ among the three groups. Conclusions: Asthma is associated with impaired acoustic voice quality in women. In this cross-sectional study, IL-5 pathway-targeted biologic therapy was associated with lower shimmer and higher HNR; prospective studies with pretreatment assessments are needed to determine whether these associations reflect treatment effects.
31 August 2026 in Medical Journal of Western Black Sea
Amaç: Bu çalışmada, Kronik Obstrüktif Akciğer Hastalığı (KOAH) olan hastalarda toraks bilgisayarlı tomografi (BT) ile ölçülen toraks ve trakea çaplarının solunum fonksiyon testleri (SFT) ile ilişkisinin incelenmesi ve bu ölçümlerin hastalığın yapısal etkilerinin değerlendirilmesindeki yerinin belirlenmesi amaçlandı.Gereç ve Yöntemler: Kesitsel tasarımla gerçekleştirilen çalışmada, 2018–2020 yılları arasında solunum fonksiyon testi ve bodipletismografi uygulanan, toraks BT görüntüleri bulunan 169 hasta retrospektif olarak incelendi. Örneklem büyüklüğü G*Power 3.1 ile a priori güç analizi kullanılarak, α=0,05 ve güç (1–β)=0,80 için minimum 104 olarak hesaplandı. Akciğer malignitesi, interstisyel akciğer hastalığı, plevral hastalık ve göğüs duvarı anomalisi olan hastalar çalışma dışı bırakıldı. Veriler SPSS 25.0 yazılımı ile analiz edildi.Bulgular: KOAH grubunda yaş ortalaması (65±10,8 vs 53±12,5 yıl) ve sigara öyküsü (30 vs 14 paket-yıl) kontrol grubundan anlamlı olarak yüksekti (p
Asthma–COPD overlap (ACO) remains therapeutically challenging, and evidence for biologic selection is limited due to the under-representation of overlap phenotypes in trials. We report a T2-high ACO patient who did not benefit from omalizumab or benralizumab but improved with dupilumab. This presents the case of a 67-year-old man with a long-term smoking history, atopy (elevated total IgE with polysensitization), eosinophilia, persistent airflow limitation, and frequent exacerbations despite optimized inhaled triple therapy. Sequential biologics included anti-IgE (omalizumab) and anti-IL-5Rα (benralizumab), with no meaningful reduction in exacerbations or improvement in lung function. After initiating dupilumab at a dose of 300 mg every 2 weeks, the patient reported a rapid improvement in symptoms, with no further exacerbations observed during the follow-up period. Pulmonary function showed a notable increase, with postbronchodilator FEV1 rising from 61 to 72% of the predicted value, and FEV1/FVC ratio improving from 69 to 84.5%. Asthma control scores increased from 12 to 20 by Week 12. Oral corticosteroid therapy was successfully discontinued, and no adverse events requiring discontinuation of dupilumab were recorded. In T2-high ACO unresponsive to anti-IgE and anti-IL-5Rα therapies, IL-4/IL-13 pathway inhibition with dupilumab may deliver a clinically meaningful benefit. Controlled studies are warranted to define its role in overlap phenotypes.